Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Positive and negative personality descriptors: UK dataset of self-referential valence, imageability and subjective frequency ratings of 300 adjectives for use in cognitive-emotional tasks

Raslescu A. et al, (2022), Data in Brief, 108831 - 108831

Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research.

Colwell MJ. et al, (2022), Transl Psychiatry, 12

Can You Feel the Burn? Using Neuroimaging to Illuminate the Mechanisms of Mindfulness Interventions for Pain.

Gillespie A. and Harmer CJ., (2022), Am J Psychiatry, 179, 705 - 707

Associations Between Statin Use and Negative Affective Bias During COVID-19: An Observational, Longitudinal UK Study Investigating Depression Vulnerability.

Gillespie AL. et al, (2022), Biol Psychiatry

Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia.

Krajner F. et al, (2022), NPJ Schizophr, 8

Online behavioural activation during the COVID-19 pandemic decreases depression and negative affective bias.

Ruzickova T. et al, (2021), Psychol Med, 1 - 18

Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial.

Xiao L. et al, (2021), Psychol Med, 51, 1166 - 1174

Translating the promise of 5HT4 receptor agonists for the treatment of depression.

Murphy SE. et al, (2021), Psychol Med, 51, 1111 - 1120

Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia.

McQueen G. et al, (2021), Schizophr Bull, 47, 662 - 671

DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia.

Hannon E. et al, (2021), Elife, 10

Longitudinal DNA methylation changes associated with improvement of psychotic symptoms during clozapine treatment

Gillespie A. et al, (2020), EUROPEAN NEUROPSYCHOPHARMACOLOGY, 31, S13 - S14

Risk factors for depression vulnerability during the COVID-19 pandemic: findings from the Oxford COSIE (COVID-19, Social Isolation and Emotion) Study

Gillespie A. et al, (2020), EUROPEAN NEUROPSYCHOPHARMACOLOGY, 40, S417 - S418

Self-reported Rates of Abuse, Neglect, and Bullying Experienced by Transgender and Gender-Nonbinary Adolescents in China.

Peng K. et al, (2019), JAMA Netw Open, 2

Health care and mental wellbeing in the transgender and gender-diverse Chinese population.

Zhu X. et al, (2019), Lancet Diabetes Endocrinol, 7, 339 - 341

S146. EFFECT OF CLOZAPINE ON REGIONAL CEREBRAL BLOOD FLOW IN TREATMENT-RESISTANT SCHIZOPHRENIA

Sendt K-V. et al, (2018), Schizophrenia bulletin, 44, S382 - S382

Applying the higher education academy framework for partnership in learning and teaching in higher education to online partnership learning communities: A case study and an extended model

Kravariti E. et al, (2018), Teaching and Learning Inquiry, 6, 143 - 164

SU116. Longitudinal Epigenetic Analysis of Clozapine Use in Treatment-Resistant Schizophrenia

Gillespie A. et al, (2017), Schizophrenia bulletin, 43, S203 - S203

Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review

Gillespie AL. et al, (2017), BMC Psychiatry, 17

Include forthcoming?